Revolution Medicines, a biotech firm, chose to remain independent despite significant takeover interest, a decision validated by its pancreatic cancer breakthrough. This strategic choice highlights the company's confidence in its standalone growth potential and pipeline.
Revolution Medicines Opts for Independence After Pancreatic Cancer Breakthrough
biotechpharmaceuticalscancer-researchcorporate-strategytakeover-defense
